Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 15, 2014

BioPharm International

  • BioPharm International-09-15-2014
  • Volume 2014 eBook
  • Issue 3

Weighing Clinical Trial Outsourcing Options

Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.

 

Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.
 

Read this article

from BioPharm International’s 2014 Outsourcing Strategies eBook.

View other articles in the

2014 Outsourcing Strategies eBook

.

 

 

 

 

 

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.